FRISQ ANNUAL REPORT 2021

This publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.


Through our platform for collaboration, we support the digitalization of health care - so that every patient gets continuous access to
the right care,
at the right point in time
FRISQ

Content

"We have 1.3% canceled operations with patients who use FRISQ Care, which is significantly lower than for those who do not choose to use the solution. This could potentially save us up to 1.7 million SEK just for our clinic and a huge amount of work for the care staff who have to change the schedule or stand with empty operating rooms ..

There is so little resources needed to monitor the system. One person can handle and monitor several hundred patients and we can be sure that we get notified if something deviates so that we need to take action. So with FRISQ, we can deliver more needs-driven care instead of routine and it can save us thousands of calls and hundreds of visits per year.

- Ida Kindlund, digital project leader at Capio Orthopedics

"For us, it is crucial to work with modern, digital solutions so that we can continue to deliver world-class orthopedics. With FRISQ Care, we experience better resource utilization and improved collaboration based on quality-assured processes. In addition, a completely new way of involving the patient is made possible and many activities that previously required care staff can now easily be performed by the patient.

- Tobias Wirén, business area manager at Capio

CEO-WORD

2021 – a commercial breakthrough

Omikron's entry into the market casued a setback at a time when we hoped to be able to look ahead. The pandemic has posed huge challenges for society at large and the healthcare sector in particular - the system, the staff and the decision-makers have really been put to the test. At the same time, it has been very encouraging to see many of the changes that have been made in such a short space of time to meet the very real and urgent needs. The use of digital solutions has become natural in some parts of the system, but unfortunately the effects of the pandemic have also meant that the integration and subsequent implementation of real innovation has been slowed or put on hold in many cases due to lack of resources.

We are therefore extra proud of what we have managed to achieve during the year, despite these external challenges. We have continuously been expanding our cooperation with a growing number of private healthcare providers and more businesses within these healthcare companies throughout the year. We have closed two multi-year contracts with Capio, regarding broad implementation of the product in two business areas: Capio Orthopedics and Capio Elderly- and Mobile care. Those new agreements have been signed after successful pilot projects, which really proves that FRISQ Care brings value that our customers are willing to pay for. FRISQ Care has been positively received at Capio and the software is said to make it "easy to do the right" whilst increasing patient safety, improving collaboration across the care team and making the meeting with the patient a better experience. I'm extra proud of the results highlighted by Capio Orthopedics that shows that the use of FRISQ Care helps Capio to deliver needs-based care based on the information provided by the patient in FRISQ Care. Having the patient involved not only means that they can be co-producers in their care and share information and off-load the care personnel, it also means that the patients are well-informed throughout the care journey which in turn decreases the need to cancel surgeries last minute.

We also managed to close our first deal with the private care giver Aleris. FRISQ and Aleris, together with Aleris-owned BB Stockholm and Ultragyn, entered into a collaboration to implement digital, interactive care plans to strengthen the collaboration between the prospective parent couple and the midwife clinic. The ambition of the project is to streamline resource utilization through modernized working methods and to simplify and improve the care journey for both the pregnant woman and the care staff. The project has gained medial awareness in the industry, which underlines both the relevance and the level of innovation the project brings.

The collaboration with pharmaceutical company UCB breaks new grounds for us as a business and shows that FRISQ Care can add value in many different business segments.

The development team has continued the effort to significantly improve the performance and scalability of the core FRISQ platform. In January, we rolled out a new and even more user-friendly and accessible patient solution that has received very good feedback from our users. The web-based solution is built to encourage and motivate patients to follow their care plans, and it's also developed to deliver a more personalized care experience, customized to individual needs. The FRISQ platform now also makes it possible for patient reported data to be used, subject to explicit approval, in a clinical setting. The handling of data, has been significantly improved for advanced analysis, in particular from a time perspective. Finally, the platform has been extended with a service to allow third parties (i.e. external quality registries) access to relevant analytical data collected as part of the treatment processes. This is very significant in providing meaningful insight for clinicians, medical staff and researchers.

We have also hired key staff during the year to make sure we have the right line-up of professionals who can support and lead the work with growing and scaling the business. The new issue recently done gives us a financial ground to stand on, making us ready to accelerate the company's positive commercial development in a time when both public and private healthcare are once again interested in investing in digital tools to improve the patient experience and streamline care delivery to create better outcomes for all.

We feel a positive momentum and we are very much looking forward to an exciting 2022!

George Thaw, CEO

Short information about FRISQ

FRISQ is a Swedish healthtech company specialized in **digitalizing health care processes**. The company has developed the software solution FRISQ Care since 2017.

FRISQ Care is a SaaS-platform that enables **efficient collaboration** with and around the patient through **personalized careplans**.

Team with 30 people, many with a long experience from business-, IT- and process development within the health care sector. Based on Sweden and UK, all development is done in Sweden.

Listed on Nasdaq First North since 2016. Major onwers like Swedbank Robur funds.

Customers in private and public care such as; **Västra Götalandsregionen** (KOL-Centrum Sahlgrenska), **Region Stockholm** (Karolinska Institutet and TioHundra), **Capio** (Orthopedics and Geriatrics) and **Aleris** (maternity care)

Benefits with FRISQ Care

Engages and **involves patients** in their care, which can lead to **better health outcomes** and **relieve care staff.**



Increased productivity and better use of **valuable resources**.

Delivers data that can contribute to **valuable insights** and thus enable **higher national quality** in health care.

FRISQ brings together care activities in individualized, digital care plans that can be shared between care teams and patients

Enables collaboration with efficient progression through the care plan

The dynamic and interactive approach with a shared care plan at the center makes it easier to coordinate activities and collaborate efficiently and in real-time with and around the patient. FRISQ Care manages and monitors each step of a care journey and with our support system that automatically reminds about activities, FRISQ Care offers progression in the care plan with minimum resource requirements. This enables an integrated and qualitative way of working across morbidities and interdisciplinary care teams – maximizing utilization of valuable resources in every step of the care journey. Integration with the EMR system also means that healthcare staff save time and that the documentation is done in a standardized way.



FRISQ is the only technical solution that supports the proposed legislation for a 'patient contract', i.e. engaging patient in their patient journeys"

– Government report: 'God och nära vård' April 2020

Empowers and engages patients in their journey towards the best possible health outcome

It should be easy to be a patient and they should feel safe and in control in every step of the care journey. FRISQ for patients is a digital health care support improving the care experiences and outcomes along the entire care journey - for patients as well as care givers. It provides a unique way for patients to be fully informed and involved in every step of their care journey – a patient journey tailored to their individual needs.

With a dynamic and interactive overview of their care, patients will have easy-access to their personal care plan and relevant information needed in every step of the care journey. By involving and engaging patients in their care and in the decisions taken, FRISQ Care encourages, supports, and empowers people to take control over and manage a larger part of their health conditions at the same time as they get the best possible support in doing so.

The roll-out of an improved patient solution

In January 2022, we started the broad roll-out of a completely new patient solution – a user-friendly web app solution developed for almost 12 months - with and for our customers and their patients' needs. The solution has received very positive feedback from customers who have praised the user-friendliness. With FRISQ Care, patients will have easy-access to their personal care plan and relevant information needed in every step of the care journey. With FRISQ Care's automatic monitoring and reminders of activities, both care staff and patients can be reassured that the right things are done at the right time which means secured progression in the care plan with minimum resource requirements.

Ensures that patients are fully informed through easy access to their care plan

- ✓ Userfriendly overview of the patients' care activities with relevant information in every step of the care journey
- ✓ Overview of tasks to be performed throughout the care journey
- ✓ Access from any device, No download needed, Easy to on-board the patients
- ✓ Easy and secure authentication: supports several authentication methods including bank ID for the Swedish market.
- ✓ Intuitive design tailored to the device you're using (PC, iPad, Mobile)
- ✓ Pausing and resuming activities with the help of autosaving function

Delivers a personalized care experience

- ✓ Questions tailored to individual patient situation: Possibility to customize forms with rules & expressions.
- ✓ Automatic adaption of activities based on situation
- ✓ Content tailored to individual needs
- ✓ Relevant and engaging content - integrate videos and images to enrich the experience
- ✓ Customize rules to make patient notified when needed

Turns patients into active co-producers to use valuable resources in the best possible way

- ✓ Patients shares information with the care team and answer questionnaires on their own, from where it suits them
- ✓ Patients get relevant information prior to meetings to make them fully informed and prepared

> *Congratulations to the new patient solution. I'm impressed and I strongly believe that this will make it even easier to engage the patients in their own care"*
>
> */User from Capio Arto Clinic*



User-friendly overview of the whole careplan



Meeting notifications

Right information at the right point in time



Answer questions in customized forms



Continuous learning that can lead to better outcomes for all

FRISQ Care enables collection of data at all stages of the care plan, which can provide valuable insights - for the patient, for the business or for research purposes.

FRISQ Care as an efficient support in research

FRISQ Care is not only providing insights to clinical work - the solution is also being used as a support in various research projects spanning from treatment of severe asthma and COPD to cancer treatments. One example is the ongoing collaboration with Karolinska Institutet to evaluate how treatment methods can impact sexual function after treatment of rectal cancer.

> FRISQ Care is a perfect support for us - working more digitally gives us completely new opportunities. We can ask the same question on several occasions, study participants can easily answer and the data automatically enters our system, which saves a lot of time and work for us. Previously, we sent questionnaires by post and it was both time consuming to send and to enter the data manually in the system and also the postage was expensive. With FRISQ, it is much easier to follow up, we can get more data and we can create unique profiles. Avoiding loose papers with sensitive information also feels safe from an information-sharing perspective.
>
> \- Christian Bucchli, Associate Professor of Surgery

SaaS solution that can be integrated with approved third parties

FRISQ Care is a SaaS (Software as a Service) platform developed to meet the comprehensive regulatory standards for patient safety and to protect against unauthorized access to confidential patient information.

- ✓ Integrations to facilitate an efficient exchange of patient data with our customers' medical record systems.
- ✓ Export of data for business and process analysis.
- ✓ API to enable uploading of data to third party national and international quality and research registers.

OUTPATIENT CARE

- Care processes including assessment, treatment and follow-up
- Internet-based treatment
- Rules engine that can, for example, be used for home monitoring
- Web + waiting room application



INPATIENT CARE

- Care processes for inpatient wards
- Overview of inpatients, activities and priorities
- Web + TV



FRISQ Care – a support for different morbidities, for in- and outpatient care

With an adaptive SaaS solution, we can deliver value to a variety of customers and needs across the care sector, spanning across morbidities and types of care delivery: inpatient, outpatient and mobile care.

CUSTOMERS AND PARTNERS IN PUBLIC AND PRIVATE SECTORS

Karolinska Institutet · Aleris · Capio · Capio · Region Stockholm · Västra Götalandsregionen · Sahlgrenska Universitetssjukhuset · Rygg Kirurgiskt Centrum · CGM · ISAR · Cerner

COVERING DIFFERENT PATIENT GROUPS

eHälsomyndigheten

Många ringer till oss om covidbevis. Covidbevis är endast till för resor. Läs mer under Nyheter och Frågor och

Nyheter → 2020 → Pandemin har både accelererat och bromsat utvecklingen inom e-hälsa

Pandemin har både accelererat och bromsat utvecklingen inom e-hälsa

Coronapandemin har fungerat både som gas och broms på e-hälsoområdet. Det visar E-hälsomyndighetens Årsrapport 2020 som belyser digitaliseringen inom hälso- och sjukvård och socialtjänst. Av rapporten framgår också att befintliga nationella kvalitetsregister har använts på delvis nya sätt för att följa och planera vård och omsorg.

Agenda Events Reports Platforms WORLD ECONOMIC FORUM Sign up

Industry Agenda | COVID-19 | Healthcare Delivery | Global Health

28 million elective surgeries may be cancelled worldwide: how non-COVID-19 medical care is suffering

https://www.ehalsomyndigheten.se/globalassets/dokument/arsrapporter/arsrapport-2020---pandemi-och-e-halsa.pdf

– De investeringar som gjorts tidigare i digitala lösningar har samhället kunnat dra nytta av under coronapandemin. Digitala möten och användningen av e-tjänster som 1177.se har ökat markant. Samtidigt har pandemin haft en hämmande effekt när planerade it-projekt har skjutits på framtiden, säger Max Herulf, läkare och utredare på E-hälsomyndigheten.

https://spor.se/wp-content/uploads/2020/11/Pandemin-har-bade-accelererat-och-bromsat-utvecklingen-inom-e-halsa-%E2%80%A2-E-halsomyndigheten.pdf

The pandemic both paused and accelerated the digital innovation

The Covid 19 pandemic has forced Swedish healthcare to concentrate on acute crisis management, and as a consequence of this, many large digital investments have been paused or canceled. At the same time, the pandemic has meant that we have seen a large increase in the use of digital tools - something that is now paving the way for the next generation of investments.

Healthcare has been severely affected by the pandemic over the past two years, and both management decisions and resources have needed to be concentrated on crisis management. One of the many consequences is that large investments in digital innovation have in many cases failed to materialize.

At the same time, the health prevention measures during the pandemic meant that the use of existing digital solutions increased dramatically. Digital meetings and increased use of e-services became a necessity to prevent the spread of infection.

Now the care is approaching a more normal situation, but with a large care debt to pay off. It creates both needs and opportunities for the next step in digitalisation: Healthcare must find ways to streamline and decision-makers now have more time to decide on investments needed to modernize and healthcare in accordance with Sweden's vision eHealth 2025.

In addition, one can build on the lessons learned from the fact that both patients and staff now make greater use of the e-services available.

The signals from politics are clear. In February 2022, the Västra Götaland region decided to increase the proportion of digital care visits to at least 20 percent by 2024 - a tripling from 6.3% in 2021! This and other decided goals in the sector will need to develop digital care processes that are shaped with and around patients.

- The management of the so-called care debt created by the pandemic will require that the work with innovation and digitalisation continues. At the same time, lessons learned from the covid-19 pandemic can serve as good examples and thus increase the speed of further development work, "says Ulrika Kruse, Chief Commercial Officer at FRISQ.

Capio elderly- and mobile care implement FRISQ Care in large scale

- You do so much of the work together with the patient and I feel that the meeting with the patient is better, says unit manager Arjeta Buqinca.

What does the digitalisation of healthcare look like in practice? How can it do more than just replace physical activities with digital equivalents, to support better and more effective collaboration between healthcare teams and patients?

A good example is Capio, where the use of FRISQ Care as a platform is widely implemented, both in geriatric care and orthopedics. Within Capio's departments for geriatrics and rehab, the solution is now used in 19 units in 8 different business areas, which involve both outpatient and inpatient care.

In the area of SGV (Coherent Geriatric Care), it leads to a safer return to the home after inpatient rehabilitation. Nurses also say that they experience increased time with patients by removing much of the time that is otherwise needed for record keeping after patient visits - with FRISQ Care, this is done directly in the meeting and with the patient.

The platform also creates more effective coordination because everyone in the care teams has access to what has been done and what needs to be done in a clear and user-friendly way.

- We have improved many of our quality parameters and it makes it easier to have routines and digital checklists, says Arjeta Buqinca, unit manager in Vårberg. "FRISQ Care makes it easier for all employees to do the right thing at the right time for all patients, while at the same time facilitating documentation and avoiding duplication of work. The way of working also feels more person-centered because you do so much of the work together with the patient and I feel that the meeting with the patient is better ".

- That we maintain the same quality and high patient safety in all our operations is crucial, says patient area manager for Capio Geriatrics Petter Nordenhäll. Business area manager Thorleif Nilsen adds: "The structured workflow also means that all documentation is done in a standardized way and reminds us of the various measures we must take with all our patients. It also feels good to be able to offer our employees a modern way of working ", comments Thorleif Nilsen,

The implementation process has been fast. "It is a sign of a fantastic collaboration to implement such a platform in just 6 months, from pilot in 2 units to almost full-scale in 19 units within the business area, including new processes and training of all staff. Kudos to the team on both sides! ". says Patrik Mattsson, Head of Customer Success at FRISQ ..



Improving maternity care with digitalised care plans

FRISQ and Aleris have together with Aleris-owned BB Stockholm and Ultragyn entered into a collaboration to implement a digital, interactive care plan in order to strengthen the collaboration between the prospective parent couple, the midwife clinic and the delivery unit. The ambition of the project is to streamline resource utilization through modernized working methods and to simplify and improve the care journey for both the pregnant woman and the care staff.

Maternity care is facing major challenges and needs to find new ways of working for the pregnant woman to receive the care she needs and expects. Therefore, the Swedish healthtech company FRISQ and Aleris, one of Sweden's largest private care providers, are initiating a collaboration to establish a more digitalized and automated care flow based on the pregnant woman's individual needs. The ambition with the digitalization is to ensure that the pregnant woman is well-informed and involved in her care, to achieve increased quality in the care offered, and to relieve the midwife with tasks that the woman can, and often wants, take responsibility for herself.

"With a systematized and digitalized way of working, we believe that we can create better conditions and increase participation in care for the pregnant woman and at the same time ease the work for the midwife. The digital care plan creates a common foundation and ensures that basic programs and regional guidelines are followed in a safe way based on individual needs, which is completely in line with the region's work on standardized care processes. The fact that the care recipient becomes an active co-producer also relieves the hard-pressed maternity care", says Åsa Edberg, CEO of Aleris Ultragyn.

An eventful year for FRISQ

January

Published a series of articles that, based on empirical evidences, shows a strong demand for improved digital tools in the healthcare sector.

February

Was nominated Digital Expertise Partner in a contract with Gravitate Health, a public-private partnership financed by the EU Commission and led by the University of Oslo in cooperation with Pfizer.

March

Launched a module that admits automatic information transfers to the national quality registers.
Appointed Ulrika Jones as CFO.

April

Reported a Q1 turnover exceeding previous full year.

May

Migration to new data centre infrastructure, managed by the health care division of Iver, for added scalability and security.

July

Signed a five years agreement with Capio Elderly and Mobile Care., replacing a previous pilot agreement, after FRISQ Care had been evaluated in competition with other systems.

September

September: Launched a new version of the forms engine allowing configuration of forms with advanced conditions and expressions which facilitates more dynamic and personalized care plans.

October

FRISQ has started up the use of about 50% of Capios Geriatrics units in Stockholm. The implementation and training of care staff continues on an ongoing basis.

November

Entered into an agreement with biotechnology companies UCB, to collaborate with selected clinics to design comprehensive, digitalized care plans for patients suffering from osteoporosis.

December

Signed a credit facility of SEK 15 million while intensifying talks to secure long-term financing.
Entered into a collaboration with Aleris, Aleris-owned BB Stockholm and Ultragyn to improve maternity care with digitalised care plans.

Board of Directors

MATS LINDSTRAND
Chairman

Mats has had a long career as a management consultant, including 10 years as Director at McKinsey & Company, before founding FRISQ in 2009. Over the past 8 years he has worked as entrepreneur and adviser to several international and government committees. Mats is a Member of the Boards of Erik Andersson Gruppen AB and Axolot Solutions AB.

Education: M.Sc. Civil Engineering from the Royal Institute of Technology in Stockholm; MBA from Columbia Business School in New York.

Warrants: –
Shareholding: 1 971 351

GÖRAN HÄGGLUND
Director

Göran has had a significant career in politics. He was elected to parliament in 1991 and served as party leader for the Christian Democrat Party (2004-15) and Minister of Social Affaris. In recent years, he has been extensively involved in health and healthcare issues, e.g., as Director for Aleris and Senior adviser at the PR agency Narva. Göran is Chairman of Systembolaget, and a Member of the Boards of Feelgood AB, Samtrafiken i Sverige AB, Ellevio AB, Forska!Sverige.

Education: Industry-wide training in the insurance sector; in-house training in the finance sector.

Warrants: –
Shareholding: –

PER EGON JOHANSSON
Director

Per Egon has many years' experience in politics, including as Undersecretary at the Ministry of Transportation (1991-94). He has extensive experience as adviser and management consultant, e.g., in the pharmaceutical industry, and from a range of operational managerial positions as e.g., CEO of Bilprovningen.
Per Egon is a Board Member of Almvik Holding AB, Raoul Wallenbergskolorna AB, Förarprov, Trafikverket.

Education: Economist, University of Gothenburg.

Warrants: –
Shareholding: 18 600

LARS BJÖRK
Director

Lars has extensive experience from the tech industry. He worked at Qlik for 17 years, the last ten years as CEO. The international expansion carried out under Lars's leadership is among the most successful in Swedish tech history.
Lars is a Board Member of Allone AB, Shift Technologies, 1337AB, and Privitar

Education: Master in Business Administration, Lund University.

Warrants: 300 000
Shareholding: 485 788

Leadership team

GEORGE THAW

VD FRISQ HOLDING & FRISQ AB

George har dokumenterad erfarenhet av att George has documented experience of creating and driving growth in global SaaS companies - within and outside the healthcare sector. He has developed business strategies that have been successfully rolled out through cross-functional, global teams

Education: Master of Business Law and Marketing from Strathclyde University, UK

Warrants: –

Shareholding: -

ULRIKA JONES

CHIEF FINANCIAL OFFICER

Experienced CEO / COO with a successful track record in Performance Management, Risk & Compliance, Revenue Generation, Change & Project Management, Financial Analysis & Controlling, Corporate Governance, Team Coaching & Development, Business & Process Development and M&A.

Education: Leadership (IHM), Law & Economics (Stockholm University),

Warrants: –

Shareholding: -

PATRIK MATTSSON

CHEIF CUSTOMER SUCCESS OFFICER

Patrik has extensive experience of digitalisation issues and leadership in healthcare. He has previously been unit manager in health and care, e-Health, digitalisation in the Västra Götaland region.

Education: IT Management studies at the University of Gothenburg; courses in leadership and project management.

Teckningsoptioner: 50,000

Aktieinnehav: 1 853

PETER ELLEBY

CHIEF TECHNICAL ADVISOR

Previously CTO for Anatwine, the e-commerce integration platform acquired by Zalando. He was also CTO for Greenlight, one of the largest independent digital agencies in the UK, VP of Engineering for Touch Clarity (acquired first by Omniture and Adobe), Board Adviser to Qubit, as well as CTO and CIO for Powa Technologies, the UK payments technology unicorn.

Education: Master of Science in Engineering – Technical University of Denmark and Brunel University London.

Warrants: –

Shareholding: -

ULRIKA KRUSE

CHIEF REVENUE OFFICER

25+ years of experience in leading commercial roles. Has successfully built and led successful sales departments in startups and large companies by introducing goal-oriented, measurable, efficient and commercially scalable sales processes.

Education: HR at Stockholm University

Warrants: –

Shareholding: -

CASPER WINSNES

CHIEF INNOVATION OFFICER

Casper has successful developed and run several notable e-health initiatives in Sweden. His previous positions included Chief Innovation Officer and Project Manager with focus on enterprise architecture. Prior to FRISQ Casper worked for Chorus, Vattenfall and Gartner

Education: Business, Stockholm University

Warrants: 150 000 (own and related party holdings)

Shareholding: 65 000 (indirect)

LOVISA SUNNERHOLM

CHIEF MARKETING OFFICER

Solid experience in strategy, marketing and communication. Has conducted marketing and change work at Electrolux's globally, worked with B2B & B2C at Google and has extensive experience from the agency world where she has worked with branding & communication strategy, planning and activation with a strong focus on PR and digital.

Education: Master of Economics, Stockholm School of Economics

Warrants: –

Shareholding: -

KAREN VENTURA

CHIEF PRODUCT OFFICER

Broad cross-functional competence and a long experience of developing and leading complex multidisciplinary delivery- and product development teams. Has previously worked with product development at EMIS Health and Servelec Healthcare

Education: O levels Math, Science, Sociology at Astrea Academy Trust

Warrants: –

Shareholding: -

ROGER EVANS

HEAD OF FRISQ UK

35+ years of extensive international public and private sector business consulting experience with customers such as Astra Pharma (all product companies), Akzo Nobel, AstraZeneca, Bayer Pharmaceuticals etc. Has been a non-executive director of the NHS personnel group.

Education: Pharma, University of London, MBA from York University,Toronto

Warrants: –

Shareholding: -

FRISQ's share

Depending on context, "FRISQ" pertains to FRISQ Holding AB (publ), org. no. 556959-2867 (a Swedish public limited liability company), or the group of companies in which FRISQ Holding is the parent company ("the Group"). FRISQ has been listed on Nasdaq First North under the ticker symbol "FRISQ" with the ISIN code SE0006994539 since October 12, 2016. FRISQ's share performance in 2020 was -41,3% compared to Nasdaq First North ALL, which was +9,8%. The share price closed at 2,30 SEK at year end, corresponding to a market capitalization of SEK 110,3 million based on outstanding shares and shares under registration.

The number of shares increased during the year from 32,204,773 to 47,954,773 which was the number of share at the end of the year.

TRADE IN THE SHARE

During 2021, 11.099.391 FRISQ shares were traded on Nasdaq First North, corresponding to 23 percent of the average number of outstanding shares. The average trading volume was 43.781 shares per day during the year.

CERTIFIED ADVISER AT FIRST NORTH

All companies traded on Nasdaq First North have a Certified Adviser that guides and supports the company. FRISQ's Certified Adviser is FNCA Sweden AB FNCA holds no shares in FRISQ Holding AB. info@fnca.se, +46 (0)8 528 00 399.

SHARE CAPITAL PERFORMANCE IN 2021

FRISQ Holding AB's share capital totaled 2,397,738.65 SEK at year-end, distributed over 47.954.773 shares with a quota value of 0.05 SEK.

In October 2020, a directed issue was carried out with deviation from the shareholders' preferential rights, as approved by the Extraordinary General Meeting held on November 4, 2020. The issue contributed approximately SEK 78.7 million to FRISQ before deduction of related costs.

The net proceeds are primarily to be used to increase the pace of sales and implementation efforts. The issue implies a dilution of 32.84 percent, as the number of shares increased by 15,750,000 to 47,954,773 . The subscription price was SEK 5.0 per share. The share capital increased by SEK 787,500.00, from SEK 1,610,238.65 to SEK 2,397,738.65.

SHARE CAPITAL DEVELOPMENT AFTER THE PERIOD

The rights issue, which took place in March. 2021, at which time the number of shares increased by 15.080.,000 from 47,954,773 to 63.034.773

OWNERSHIP STRUCTURE

At year end, FRISQ had a total of 4.254 registered shareholders, of which, Swedbank Robur Fonder, UBS on behalf of investor and Nordic Cross Asset Management, together held 19,2% of all outstanding shares and votes.

PROPOSED DIVIDEND AND DIVIDEND POLICY

No dividend distribution is proposed for FRISQ's shareholders. A dividend distribution to shareholders will not be proposed until the Company achieves stable profitability. Available funds will continue to be applied to, among other things, strengthening the organization, commercializing FRISQ's products and expanding internationally. The size of any future dividends will be determined by a range of factors including earnings, financial position, cash flow, liquidity, and working capital requirement.

Shareholders and share data

Shareholders	NO OF SHARES	SHARE (%) OF CAPITAL AND VOTES
Swedbank Robur Fonder	4 426 156	9,23%
UBS för klients räkning	2 500 000	5,21%
Nordic Cross Asset Management	2 287 550	4,77%
M. Lindstrand Investment AB och privat	1 971 351	4,11%
Avanza Pension	1 721 311	3,59%
Loer AB	1 255 710	2,62%
Amadra AB	562 297	1,17%
Cloverhill Holdings Ltd	500 000	1,04%
Stephan Clarkson	498 591	1,04%
Lars Björk	485 788	1,01%

Source: Monitor and Modular Finance AB

VOLUME AND PRICE TRENDS, 2021



The Board of Directors and the CEO for Frisq Holding AB (Publ), org. nr. 559026-8016, presents the following report for the financial year 2021-01-01-- 2021-12-31.

Administration report

The Business
FRISQ develops and sells software to the care and healthcare sector. FRISQ's software improves the efficiency of care delivery and engages patients in their own care, while also supporting interactive communication between participants in the healthcare chain. The products are designed as modules and sold as a service provided by FRISQ and are delivered to clients mainly as a SaaS (Software as a Service) solution. The products are adaptable and can be integrated with customers' existing IT environments..

The Company's first commercial product, FRISQ Care, is adapted for computers, tablets and cell phones, giving care providers and patients the capacity to work clearly and efficiently with forward-looking healthcare processes, independent of diagnosis.

FRISQ Care gives patients information on their treatment and care history, directly on their phones, and gives the care team a digital tool for the patient's treatment plan that enables efficient communication among members of the care team and with the patient. This provides patients with a clear overview of their healthcare journey and creates patient engagement.

FRISQ Care automates large parts of healthcare's cumbersome administrative information management and documentation processes, freeing up time for healthcare professionals. FRISQ Care is principally a complement to existing healthcare systems, such as the electronic health record systems used by virtually all care providers in the western world. As a SaaS solution, FRISQ Care is globally scalable and is designed to meet international standards that govern the regulatory framework for digitalizing healthcare and medical information..

The company's headquarter is in Stockholm.

Significant events during 2021
• FRISQ entered into an agreement with biotechnology companies UCB and Amgen, to collaborate with selected clinics to design comprehensive, digitalized care plans for patients suffering from osteoporosis. The order value for FRISQ is approximately 0,5 Mkr, excluding any additional orders for implementation and license revenues that may be added for additional clinics that join.

• FRISQ and Aleris have, together with Aleris-owned BB Stockholm and Ultragyn, entered into a pilot project to strengthen the collaboration between the prospective parent couple, the midwife clinic and the delivery unit. The ambition of the project is to streamline resource utilization through modernized working methods and to simplify and improve the care journey for both the pregnant woman and the care staff. The value of the project is 0,2 Mkr and the project runs for 12 months.

• FRISQ has signed a commercial agreement with Capio Elderly and Mobile Care. The agreement runs for 5 years and the order value amounts to 15 Mkr. The agreement entered into force on 1 July 2021 and replaces the previous pilot agreement, after FRISQ Care has been evaluated in competition with other systems.

Frisq Holding AB (publ)
556959-2867

Multiyear comparison and key ratios, group

	2021	2020	2019	2018	2017
Net sales	4 891	1 367	1 936	5 255	248
Operating profit/loss	-80 417	-208 060	-73 457	-46 273	-32 701
Profit/loss for the year	-80 386	-229 115	-73 763	-42 015	-24 894
Earnings per share, SEK	-1,7	-7,3	-3,2	-2,2	-1,5
Balance sheet total	40 823	116 251	203 642	214 597	199 717
Equity/asset ratio	53%	87%	92%	93%	96%
Number of employees, average	23	31	25	14	14
Number of employees, end of period	25	29	33	17	14

Definition of key figures, see note 43

Financial overview group

Consolidated net revenue for the year amounted to 4 891 Tkr (1 367), includes a higher ratio of recurring license-based revenues than did last year. However, the ongoing pandemic has slowed down sales and rollouts. Other operating income relates primarily to EU-financed commercially based innovation projects amounted to 1 596 Tkr (442).

Consolidated costs before depreciation and write-down are primarily driven by staff costs, development and operational expenditures, amounted to 66 942 Tkr (76 509) and is reported net including capitalized work on own account which amounted to 3 538 Tkr (4 064). The cost reduction is primarily related to fewer employees.

Total depreciation and write-down of tangible and intangible assets amounted to 19 962 Tkr (133 360). Operating losses amounted to -80 417 Tkr (-208 060) of which 0 Tkr (104 490) relates to write-down of goodwill. Net financial costs amounted to 31 Tkr (-119) and relate primarily to interest costs on right-of-use assets.

Total comprehensive income amounted to -80 386 Tkr (-229 115), of which 0 Tkr (125 436) Tkr relates to the write down of goodwill and the reversal of tax asset.

Liquidity and financing

The Company is fairly young and has adopted a conservative policy with low capitalization and high depreciation rates. Cash balance at the end of the period was 13 072 Tkr (87 811). After the year end the Company has initiated a direct issue and rights issue but even with that new financing the Company will not have sufficient funds to cover the next 12 months, with the current forecast..

Significant events after the balance sheet date

- After a 12-month pilot project, Capio Orthopedics now signs a three-year agreement with FRISQ. The purpose of the agreement is to introduce the digital process support FRISQ Care in all Capio Orthopedics units in accordance with the with the offered licensing and implementation costs

- The Extra General Meeting made an amendment of the Articles of Association, which gave the Board a mandate to issue new shares.

- The Company has received a non-binding offer for the Company's operating subsidiaries FRISQ AB, FRISQ UK LTD and FRISQ USA Holding Inc (together the "Subsidiaries") for a total purchase price of approximately SEK 106 million.

- The Company has carried out a directed share issue of 15.080,000 shares at the issue price of one (1) SEK per share. These shares are not entitled to any rights in the rights issue

The total number of shares issued in the directed issue and the forthcoming rights issue will total a maximum of approximately 31.9 million shares, which is covered by the authorization provided to the Board mandated by the recently held Extraordinary General Meeting. Given a subscription of a total of 31.9 million shares in the two new issues, the number of shares in the company will increase from 47,954,773 to 79,924,921. The shares issued in the directed issue and the rights issue will constitute approximately 40 percent of the shares in the Company

Total cost for both the rights issue and the direct issue will approximately be 0.8 mSEK. The Company will, at full subsription of the new shares, receive a net financing of 31 .

With these new share issues, the Company is trying to secure the financial position. The Board has begun to work together with the management team to adjust costs and focus the commercial work with objective that the Company will be cash flow positive by the end of 2022.Tempest has indicated that they still are interested in purchasing Frisq subsidiaries. The Board cannot assess the probablilty that this will happen.

Group Structure

Per balance sheet date the Group is comprised of parent company FRISQ Holding AB, org. no. 556959-2867, and wholly owned subsidiaries FRISQ AB, org. no. 556783-5664, FRISQ UK Ltd, org no. 12745808 and FRISQ USA Holding Inc. The latter owns 100 percent of the capital and votes in FRISQ LLC.

The US and UK subsidiaries, are all under establishment. The Group's operating activities are conducted in FRISQ AB. The Group operates in one segment.

Significant risks and uncertainties

History of operating losses

The Company has historically posted operating losses. FRISQ is a young development company that operates in, and is trying to change, a traditionally slow-moving industry by creating digital tools to enable interactive communication between participants in the healthcare chain. The Company has posted negative results since its start. The Company's commercialization strategies may prove to be ineffective or misdirected, which may result in the Company's revenues being insufficient to finance its commitments. In the event the Company succeeds in reporting operating profits in the future, there is a risk that this will occur only after a long period of time.

Liquidity risk/financing risk

Liquidity risk, the risk of the Company experiencing difficulty in fulfilling its commitments, arises when assets and liabilities have different maturities. The Company's shortage of major recurring revenues may lead to a lack of liquidity. To ensure its survival, the Company may need additional external financing for its operating activities. The Board of Directors monitors rolling liquidity forecasts to ensure that there is sufficient liquidity to meet the needs of the Company's operating activities. The Company's cash-in-hand, including the recently closed preferential rights issue, is intended to meet the Company's capital requirements for the coming 12 months. The Board of Directors will propose to the next Annual General Meeting that the AGM authorize the Board to decide on the issue of shares and/or warrants and/or convertibles for consideration in the form of cash payment.

Dependence of key employees

The Company considers that a few key people are of particular importance to the business but deems the risk of any key person leaving their position to be low. Should this occur, there would be a medium to high short-term impact on the Company's operations.

Dependence on protection of data source code

FRISQ is reliant on and claims copyright to the data source code the Company has developed and integrated into the platform. This does not provide the same scope of protection as that provided by registrable rights. There is a risk of improper utilization/encroachment by third parties, which may have a significant adverse impact on the business's results and financial position.

Partial dependence pn EHR system suppliers

As of year-end 2021, FRISQ collaborates and/or is integrated with four EHR system suppliers that collec- tively cover approximately 95 percent of the Swedish market in terms of number of

<u>Exposure to legal and regulatory risks</u>
Several of the contracts the Company is aiming to conclude are awarded through public procurement processes. There is a risk that the Company will fail to deliver in accordance with applicable requirements specifications, which may result in cancellation of contracts already entered into or in damage claims against the Company.
The Company is also party to a number of subcon- tracts with operators who were awarded contracts through public procurement processes. There is a risk of contracts awarded to the main supplier being cancelled, which would entail termination of the main supplier's contract with FRISQ.

<u>Effects of Covid-19</u>
Since FRISQ operates in the healthcare sector, the Company is dependent on customers/healthcare professionals being available - which is difficult to predict during the current pandemic. The effects are likely to influence the company's income in the near future. The Company does not consider the valuation of retained assets has been affected by the current Covid-19 pandemic.
.
<u>Assesment of uncertainties and risks</u>
There was no material change in the assessment of risks or uncertainties during 2021.

Expected future development
During 2021 the Company focused on working with a number of strategically important customers to develop the standard offering, to enable demonstration of the product's functionality and efficiency. This goal was achieved during the year and was verifiable through objective patient engagement surveys and customer testimonials. However, the Covid-19 pandemic has been a major test on the Swedish healthcare system and is likely to be so for a long time to come. FRISQ has proven time and time again to be an important part of meeting the future challenges in healthcare, partly through the recognition of authorities and investigations, but also through the good results the Company has been able to show through, among other things, patient engagement measurements.
.
Ownership

Proposed disposition of the Compnay's profis

At the

share premium reserve	491 641 348
retained earnings	-396 369 355
net profit/loss for the year	-58 565 285
	36 706 708

The Board of Directors proposes the following

To be carried forward	36 706 708
	36 706 708

For information about the company's earnings and financial position in other respects, please refer to the income statements, balance sheets and accompanying notes set out below. All amounts, unless otherwise stated, are rounded to the nearest thousand SEK.

Financial Statements 2021

Frisq Holding AB (publ)
556959-2867

Consolidated income statement (Tkr)

	Note	2021	2020
Operating income			
Net sales	5	4 891	1 367
Other operating income	7	1 596	442
		6 487	**1 809**
Operating expenses			
Own work capitalised		3 538	4 064
Other external expenses	8, 9	-43 461	-45 379
Personnel costs	10	-27 006	-35 022
Depreciation and write-down of tangible and intangible assets	11	-19 962	-133 360
Other operating expenses		-13	-172
		-86 904	**-209 869**
Operating profit/loss		**-80 417**	**-208 060**
Profit/loss from financial items			
Financial income		94	103
Financial expenses		-63	-222
Profit/loss after financial items		**-80 386**	**-208 179**
Income tax	12	0	-20 936
PROFIT/LOSS FOR THE YEAR		**-80 386**	**-229 115**
Resultat per aktie före/efter utspädning (SEK)	23	-1,7	-7,3

Consolidated statement of comprehensive (Tkr)

	2021	2020
Profit/loss for the year	-80 386	-229 115
Other comprehensive income		
COMPREHENSIVE INCOME FOR THE YEAR	**-80 386**	**-229 115**

Frisq Holding AB (publ)
556959-2867

Consolidated balance sheet (Tkr)

	Note	Dec 31, 2021	Dec 31, 2020
ASSETS			
Non-current assets			
Capitalised expenditure for development and similar work	13	14 729	20 899
Equipment	14	578	640
Right of use assets	15	9 039	3 128
Total non-current assets		**24 346**	**24 667**
Current assets			
Account receivables	17	1 259	1 994
Current tax assets		133	48
Other receivables		960	414
Prepaid expenses and accrued income	18	1 053	1 317
Cash and cash equivalent	19	13 072	87 811
Total current assets		**16 477**	**91 584**
TOTAL ASSETS		**40 823**	**116 251**
EQUITY AND LIABILITIES			
Equity			
Share capital	20	2 398	1 610
Ongoing new issue		0	788
Other contributed capital	21	492 637	492 391
Translation reserve		5	5
Profit/loss brought forward incl net profit/loss for the year		-473 541	-393 155
Total equity		**21 499**	**101 639**
Long-term liabilities			
Lease liabilities	25	6 172	0
Total long-term liabilities		**6 172**	**0**
Current liabilities			
Lease liabilities	25	2 867	3 281
Accounts payable		4 236	5 159
Other current liabilities		1 111	992
Accrued expenses and deferred income	26	4 938	5 180
Total current liabilities		**13 152**	**14 612**
TOTAL EQUITY AND LIABILITES		**40 823**	**116 251**

Frisq Holding AB (publ)
556959-2867

Consolidated statement of changes in equity (Tkr)

	Share capital	Ongoing new issue	Other contributed capital	Translation reserve	Profit/loss brought forward inc. Net profit/loss for the year	Total equity
Opening balance, January 1, 2020	1 196	0	350 686	5	-164 040	187 847
Comprehensive income						
Profit/loss for the year					-229 115	-229 115
Total comprehensive income				**0**	**-229 115**	**-229 115**
Transactions with shareholders						
New share issue	414	788	152 127			153 329
New issue expenses			-10 801			-10 801
Warrant premium			379			379
Total transactions with shareholders	**414**	**788**	**141 705**	**0**	**0**	**142 907**
Closing balance, Dec 31, 2020	**1 610**	**788**	**492 391**	**5**	**-393 155**	**101 639**
Opening balance, January 1, 2021	1 610	788	492 391	5	-393 155	101 639
Comprehensive income						
Profit/loss for the year					-80 386	-80 386
Transactions with shareholders						
New share issue	788	-788				
Issue expenses			-119			-119
Warrant premium			365			365
Total transactions with shareholders	**788**	**-788**	**246**	**0**	**0**	**246**
Closing balance, Dec 31, 2021	**2 398**	**0**	**492 637**	**5**	**-473 541**	**21 499**

The equity is wholly attributable to the Parent Company's shareholders.

Frisq Holding AB (publ)
556959-2867

Consolidated statement of cash flow (Tkr)

	Note	2021	2020
Operating activities			
Operating profit/loss		-80 417	-208 060
Adjustment for non-cash items:			
Depreciation and write-down	11	19 962	133 360
Result on sale of intangible and tangible fixed assets		0	172
Other		365	379
Interest received etc.		94	103
Interest paid etc.		-63	-222
Income tax paid		0	0
Cash flow from operating activities before changes in working capital		**-60 059**	**-74 268**
Cash flow from changes in working capital			
Decrease (+)/increase (-) in receivables		454	2 021
Decrease (+)/increase (-) in liabilities		-1 132	2 290
Cash flow from operating activities		**-60 737**	**-69 957**
Investing activities			
Acquisition of intangible fixed assets	14	-10 425	-8 587
Acquisition of tangible fixed assets	14	-177	-601
Sale of tangible assets		0	480
Change in financial fixed assets		0	500
Cash flow from investing activities		**-10 602**	**-8 208**
Financing activities			
New share issue, net after transaction costs		-119	142 528
Amortization of lease liability	24	-3 281	-3 257
Cash flow from financing activities		**-3 400**	**139 271**
Cash flow from the period		**-74 739**	**61 106**
Cash and cash equivalents at the start of the year		87 811	26 705
Cash and cash equivalents at the end of the year	19	**13 072**	**87 811**

Frisq Holding AB (publ)
556959-2867

Parent company income statement (Tkr)

	Note	2021	2020
Operating income			
Net sales	5, 6	5 854	3 867
Other operating income	7	0	18
		5 854	**3 885**
Other external expenses	6, 8, 9	-9 701	-11 874
Personnel costs	10	-2 600	-1 325
Depreciation and write-down of tangible and intangible assets	11	0	0
Other operating expenses		-13	0
		-12 314	-13 199
Operating profit/loss		**-6 460**	**-9 314**
Resultat från finansiella poster			
Income from participation in group companies	16	-52 200	-380 000
Interest income and similar items		95	100
Interest expenses and similar items		0	0
Profit/loss after financial items		**-58 565**	**-389 214**
Income tax	12	0	0
PROFIT/LOSS FOR THE YEAR		**-58 565**	**-389 214**

Parent company statement of comprehensive income (Tkr)

	2021	2020
Profit/loss for the year	-58 565	-389 214
Other comprehensive income	0	0
COMPREHENSIVE INCOME FOR THE YEAR	**-58 565**	**-389 214**

After the year-end report was published, uncertainties around the world have led to that the sale of Frisq AB to Tempest SPV Ltd. has not been implemented. As a result, shares in Group companies have been written down, which is a deviation from previously reported figures in the year-end report.

Frisq Holding AB (publ)
556959-2867

Parent company balance sheet (Tkr)

	Note	Dec 31, 2021	Dec 31, 2020
ASSETS			
Non-current assets			
Financial assets			
Participation in group companies	16	29 063	29 063
Total non-current assets		**29 063**	**29 063**
Current assets			
Current receivables			
Receivables from group companies		600	712
Prepaid expenses and accrued income	18	25	62
		625	**774**
Cash and cash equivalent	19	10 397	68 924
Total current assets		**11 022**	**69 698**
TOTAL ASSETS		**40 085**	**98 761**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	20	2 398	1 610
Ongoing new issue		0	788
Total restricted equity		**2 398**	**2 398**
Non-restricted equity	22		
Share premium reserve		491 641	491 761
Retained earnings		-396 369	-7 521
Net profit/loss for the year		-58 565	-389 214
Total non-restricted equity		**36 707**	**95 026**
Total equity		**39 105**	**97 424**
Current liabilities			
Accounts payable		455	1 112
Tax liabilities		49	0
Other current liabilities		328	92
Accrued expenses and deferred income	26	148	133
Total current liabililties		**980**	**1 337**
TOTAL EQUITY AND LIABILITIES		**40 085**	**98 761**

Frisq Holding AB (publ)
556959-2867

Parent company statement of changes in equity (Tkr)

	Share capital	Ongoing new issue	Share premium reserve	Retained earnings and profit/loss for the year	Total equity
Opening balance, January 1, 2020	1 196	0	350 435	-7 900	343 731
Comprehensive income					
Profit/loss for the year				-389 214	-389 214
Total comprehensive income				**-389 214**	**-389 214**
Transactions with shareholders					
Non-cash issue					0
New share issue	414	788	152 127		153 329
New issue expenses			-10 801		-10 801
Warrant premium				379	379
Total transactions with shareholders	**414**	**788**	**141 326**	**379**	**142 907**
Closing balance, Dec 31, 2020	**1 610**	**788**	**491 761**	**-396 735**	**97 424**
Opening balance, January 1, 2021	1 610	788	491 761	-396 735	97 424
Comprehensive income					
Profit/loss for the year				-58 565	-58 565
Total comprehensive income				**-58 565**	**-58 565**
Transactions with shareholders					
Non-cash issue					
New share issue	788	-788			
New issue expenses			-119		-119
Warrant premium				366	366
Total transactions with shareholders	**788**	**-788**	**-119**	**366**	**247**
Closing balance, Dec 31, 2021	**2 398**	**0**	**491 641**	**-454 934**	**39 105**

Parent company statement of cash flow (Tkr)

	Note	2021	2020
Operating activities			
Operating profit/loss		-6 460	-9 314
Adjustment for non-cash items:			
Share-based compensations		366	379
Interest received etc.		95	100
Income tax paid		0	0
Cash flow from operating activities before changes in working capital		**-5 999**	**-8 835**
Cash flow from changes in working capital			
Decrease (+)/increase (-) in receivables		148	1 866
Decrease (+)/increase (-) in liabilities		-357	98
Cash flow from operating activities		**-6 208**	**-6 871**
Investing activities			
Loans granted during the year to group companies		-52 200	-87 274
Cash flow from investing activities		**-52 200**	**-87 274**
Financing activities			
New share issue, net after transaction costs		-119	142 528
Cash flow from financing activities		**-119**	**142 528**
Cash flow from the period		**-58 527**	**48 383**
Cash and cash equivalents at the start of the year		68 924	20 541
Cash and cash equivalents at the end of the year	19	**10 397**	**68 924**

NOTES

Note 1 General information

FRISQ Holding AB (publ), org. no. 556959-2867, is a Swedish public limited liability company domiciled in Stockholm, Sweden. The address of the head office is Lästmakargatan 20, 111 44 Stockholm. The share has been traded on Nasdaq First North as of October 12, 2016 under the stock symbol FRISQ.

FRISQ develops and sells software to the care and healthcare sector. FRISQ's software improves the efficiency of care delivery and engages patients in their own care, while also supporting interactive communication between participants in the healthcare chain. The products are designed as modules and sold as a service provided by FRISQ and are delivered to clients mainly as a SaaS (Software as a Service) solution. The products are adaptable and can be integrated with customers' existing IT environments.

The Group is comprised of parent company FRISQ Holding AB, org. no. 556959-2867, and wholly owned subsidiaries FRISQ AB, org. no. 556783-5664, FRISQ UK Ltd and FRISQ USA Holding Inc. The latter owns 100 percent of the capital and votes in FRISQ LLC.

This annual report and the consolidated accounts were approved by the Board of Directors and the CEO on 31 mars 2022 and will be presented for adoption at the Annual General Meeting on 5 May 2022.

All amounts are presented in SEK thousand unless otherwise indicated. Figures in parentheses refer to the year-earlier period.

Note 2 Accounting and valuation policies

Principles when preparing the Group's and the Parent Company's financial reports
The most significant accounting principles that were applied in preparing the consolidated accounts are presented below. Unless otherwise indicated, these principles were applied consistently for all periods presented in these financial statements.

The consolidated accounts were prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB) as adopted by the EU. The Swedish Financial Reporting Board's Recommendation RFR 1, Supplementary Accounting Rules for Groups, and applicable statements were also applied.

The Parent company applies the same accounting principles as the Group, with the exception of the provisions specified in Swedish Financial Reporting Board Recommendation RFR 2, Accounting for Legal Entities. Accounting principles applied by the parent company are presented in the section Accounting principles for the parent company and are uniform with the Group unless otherwise stated.

Functional currency and presentation currency
The Swedish krona (SEK) is the functional currency of the parent company and the reporting currency of the parent company and Group. The financial statements are therefore presented in SEK.

Valuation basis in the preparation of the financial statements
Assets and liabilities are recognized at historical cost.

New standards and interpretations applied by the Group
A number of new standards and interpretations to the standards will enter into force for financial years beginning on January 1, 2021. None of these are deemed to have any impact on the Group's financial reports.

New standards and interpretations that have not yet been applied by the Group
A number of new standards and interpretations to standards are effective for annual periods beginning after January 1, 2021, and have not been applied in preparing these consolidated financial statements. New standards and amendments that have not yet come into effect are not expected to have any significant impact on the Group's financial statements.

Classification of assets and liabilities
Non-current assets and liabilities consist primarily of assets and liabilities that are expected to be recovered or settled more than 12 months after the balance-sheet date. Current assets and liabilities primarily consist of assets and liabilities that are expected to be recovered or settled within 12 months of the balance-sheet date.

Consolidation policies
Subsidiaries are entities over which the Group has controlling influence. Controlling influence exists when the Group is exposed to or has the right to receive variable returns from its holding in the company and is able to use its influence over the company to affect returns.

Subsidiaries are included in the consolidated accounts from the day controlling influence is transferred to the Group. The acquisition method of accounting is used to report the Group's business combinations. The purchase price for acquisition of a subsidiary is comprised of the fair value of transferred assets, the liabilities incurred by the Group from the acquired company's former shareholders, and the shares issued by the Group. In a business combination, acquired identifiable assets and acquired liabilities are initially valued at fair value on acquisition date. Acquisition-related expenses are expensed as they arise. When the purchase price exceeds the acquired identifiable net assets, the excess amount is reported as goodwill.

Intra-group transactions, balance sheet items and unrealized gains and losses on transactions between Group companies are eliminated. Accounting principles for subsidiaries have been amended when applicable to guarantee the consistent application of the Group's principles.

Transactions in foreign currency are translated to functional currency at the exchange rate in effect on the transaction date. Assets and liabilities in foreign currency are translated to functional currency at the closing day rate. Foreign subsidiaries prepare their annual reports in foreign currency and their financial statements are translated to SEK; all assets and liabilities are translated at the closing day rate and the profit and loss statement is translated at the year's average rate. Translation differences that arise are reported in other comprehensive income for the Group and are recognized directly against Group equity. This is reported on an accumulated basis in a separate equity item, the translation reserve.

Revenue recognition
FRISQ's business model is based primarily on revenue from software licenses and implement-tation services. In addition, the Company receives compensation for a number of commercial EU grants.

<u>Accounting for commercial contracts</u>
The basic principle is that revenue is recognized in the manner that best reflects the transfer of the promised good or service/performance obligation to the customer and payment is deemed certain. Revenue from contracts is recognized through a five-step model:

(1) identify the contract, (2) separate performance obligations, (3) determine transaction price, (4) allocate the transaction price to the obligation, (5) recognize revenue when the obligations are fulfilled

If the transaction price includes variable consideration (e.g., bonuses or discounts), this is estimated and included in the transaction price.

Revenue from services delivered is recognized in the period the services are provided. In fixed-price agreements, revenue is recognized based on percentage of the total agreed-upon service delivered (i.e., of benefit to the customer). Revenue is based on actual hours worked as opposed to total hours estimated to be required for delivery. In contracts with multiple performance obligations, the transaction price is allocated to each individual performance obligation based on their stand-alone sales price. Any consequences following changes to assumptions are reported as a gain or loss during the period the revaluation occurs. For fixed-price agreements, the customer pays at agreed points in time. If the payments exceed the services delivered, a contractual liability is recognized. If the services delivered exceed the payment and payment with certainty will be received, a contract asset is recognized.

In open account contracts based on hourly price, revenue is recognized to the extent the customer receives control over the delivered services, normally on a monthly basis.

License fees are usually invoiced monthly in advance, after which the license revenue is recognized in the month to which the license fee applies.

Payment terms may specify payment in advance or after delivery, as agreed in the customer contract. Cash-settled amounts and actual outcomes are reconciled as contractually agreed and at contractually specified times. No guarantees are provided that would give rise to the disclosure of separate performance obligations.

Expenses directly related to contract formation (e.g., commissions) are posted as assets when they arise and are expensed over the contract period.

<u>Government Grants</u>
Grants are recognized at fair value as soon as there is reasonable assurance that the conditions associated with the grant will be met and thus that the grant will be received. Contributions received to cover costs are reported as other operating income.

Segment reporting
An operating segment is a part of a company that operates a business from which the company can generate revenue and incur expenses, for which operating profit/ loss is regularly reviewed by the company's chief operating decision maker, and for which independent financial information is available. The Company's operating segment reporting corresponds with internal reporting to the chief operating decision maker, who is the person that assesses the operating segment's results and decides on the allocation of resources. The Company's CEO is the chief operating decision maker.

Financial information reported to the CEO as supporting documentation for allocation of resources and assessment of the Group's results is not divided into operating segments. The Group therefore comprises one operating segment.

Remuneration of employees
<u>Salary and performance compensation</u>
Short-term employee benefits are calculated without discounting and are reported as a cost when the related services are received.

<u>Pensions</u>
For the pension plans offered by FRISQ, the Company pays a fixed premium to a pension provider. FRISQ subsequently has no legal or informal obligation to pay further premiums if the pension provider does not hold sufficient assets to pay benefits to the insured.

Consolidated profit/loss is charged with expenses as the benefits are earned, which normally coincides with the time premiums are paid. Prepaid premiums are posted as an asset when they result in a reduction in future premium payments.

Compensation upon termination
Severance pay is paid when employment is terminated pursuant to an agreement with the employee. The Group reports remaining contractual commitments as a liability in the period the agreement is made.

Foreign currency transactions
Transactions denominated in foreign currencies are converted into the functional currency at the exchange rate on the date of the transaction. Exchange gains and losses on operating receivables and liabilities are reported in operating profit, while exchange gains and losses on financial receivables and liabilities are reported as financial items. Exchange differences are recognized in the profit or loss for the period in which they arise.

Leasing
A new lease agreement is recognized as right-of- use asset and a lease liability on the balance sheet. IFRS 16 states that, in principle all leases, are recognized on the balance sheet, as no distinction is made between financial and operational leasing.

For new finance lease agreements, the fixed asset is carried at the amount equal to the leased asset's fair value or, if lower, the present value of future minimum lease payments for non-cancellable lease terms. Each lease payment is allocated between liabilities and financial expense. The lease liability, after interest, is reported as other long- and short-term liabilities.

The interest component of the financing cost is charged to the profit and loss statement over the lease term in such that the interest rate remains constant for the remaining liability.

The leased asset is depreciated to the residual value of the asset's useful life or the lease agreement duration, whichever is shorter. Extension periods may be included if the Group is reasonably certain they will be utilized.

The Group's significant lease agreements pertain to leases of office premises. The Company's marginal lending rate (currently 5 percent) is applied when discounting. If the lease agreement is amended during the lease term, the lease liability and right-of-use asset are revalued. Leasing fees are allocated between amortization of the lease liability and payment of interest. The Company applies relief rules for lease agreements in cases where the underlying asset is of low value and for short-term leases. These lease agreements are reported as an expense during the period in which they are used.

Income tax
Total tax for the Group comprises current tax and deferred tax. Income taxes are reported in profit/loss for the year, except in cases where the underlying transactions are reported in other comprehensive income or in equity; in those cases, the tax effect is reported in other comprehensive income or in equity.

Current tax is income tax for the current financial year pertaining to the year's taxable profit and the portion of the previous financial year's income tax that has not yet been reported. Current tax is calculated at the probable amount pursuant to the tax rates and tax regulations applicable on the balance sheet date.

Deferred tax is income tax on taxable profit for future financial years resulting from previous transactions or events. Deferred tax is calculated on temporary differences. A temporary difference arises when the carrying amount of an asset or liability differs from its taxable amount. Deferred tax assets are reported to the extent there are factors convincingly indicating that sufficient future taxable profit is probable.

Earnings per share
The calculation of earnings per share before dilution has been based on the Group's net profit/loss for the year in relation to the weighted average number of shares outstanding.

Intangible assets
Capitalized development costs
Capitalized development costs are reported at acquisition value less accumulated depreciation and any impairment losses. Assets are depreciated on a straight-line basis over their estimated useful lives as of the date the product is fully developed. Assets' residual values and useful lives are tested at each reporting date and adjusted as needed.

Residual values and useful lives of the assets are tested at each reporting date and adjusted as required. Capitalized development expenditure includes subcontracting and personnel costs incurred in the development of the retained asset.

Development costs are reported as intangible assets when the following conditions are met:
- It is technically feasible to complete the asset and there are adequate resources to do so
- the Company intends to complete It
- the Company can demonstrate that the asset will generate future economic benefits
- the costs attributable to the asset during its development can be reliably calculated.

Other development costs that do not meet these criteria are expenses as they arise.

Development costs that have been previously expensed are not reported as assets in subsequent periods. An assessment is made of expected useful life (normally 2-5 years) upon completion.

Tangible assets
Tangible fixed assets are reported at acquisition value less accumulated depreciation and any impairments. Acquisition value includes purchase price and expenses directly attributable to bringing the asset to the location and condition necessary for its use. Assets are depreciated on a straight-line basis over their useful lives.

Assets' residual values and useful lives are tested monthly and are adjusted as needed. Depreciation is based on the following expected useful lives:
Leasehold improvements: 5 years
Servers and technical facilities: 3 years
Equipment used for development: 2 years
Right-of-use assets: Over their useful lives
Other investments, such as those in more basic computers, cell phones, accessories and repairs/ maintenance, are expensed during the period in which they arise.

All fixed assets are reported in the Swedish subsidiary.

Disposal of fixed assets
The carrying amount of tangible an intangible assets is derecognized from the balance sheet when the item is disposed of or sold or when no future financial benefits are expected to accrue from the asset. Gains or losses on the sale or disposal of an asset are calculated as the difference between the selling price and the carrying amount of the asset (less direct selling expenses). Gains or losses are recognized as other operating income/expenses in profit or loss.

Impairment of non-financial assets
Assets that have an indefinite useful live (e.g., intangible assets not ready for use) are not amortized but are tested annually and whenever there is indication of a possible impairment requirement. The diminution of value of amortized assets is assessed when events or changes in circumstances indicate that the carrying amount may not be recoverable.

An impairment loss is reported at the amount at which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the asset's fair value less divestment costs or its value in use, whichever is greater. Value in use is calculated by discounting expected future cash flow to present value at a pre-tax discount rate that reflects the current market assessment of the time value of money and the risks associated with the asset.

The Company determines at each reporting date whether there are indications that the previous impairment of an asset (apart from goodwill) is no longer wholly or partially justified.

Impairment losses are reversed only to the extent the asset's carrying amount does not exceed the amount the Company would have reported (after depreciation) if the Company had not written down the asset. Reversals of write-downs are reported in the profit and loss statement.

Financial assets and liabilities
Financial assets
The Group classifies and values its financial assets based on the business model that manages the asset's contracted cash flows and the nature of the asset. Financial assets are classified in one of the following categories: (1) financial assets valued at amortized cost, (2) financial assets valued at fair value through other comprehensive income, or (3) financial assets valued at fair value through profit or loss.

The Group currently only has financial assets valued at amortized cost, for which the purpose of the holding is to receive contractual cash flows. These financial assets are included in current assets with the exception of items maturing more than 12 months after the close of the reporting period, which are classified as fixed assets. Valuation is at amortized cost applying the effective interest method.

When acquiring financial assets, expected credit losses are reported regularly over the holding period. When there is an increase in credit risk, reservation is made for credit losses expected to be incurred during the asset's life. Based on historical data on the payment patterns and payment capacity of current counterparties, expected credit losses are deemed to be limited.

Financial liabilities
All financial liabilities in the Group are classified and valued at amortized cost applying the effective interest method. Initial reporting is at fair value, net after transaction costs.

Accrued acquisition value
Accrued acquisition value refers to the amount to which the asset or liability was initially recognized less deductions for amortization, additions or deductions for accumulated accrual according to the effective interest method of the initial difference between the received/paid amount and the amount to be paid/received on the due date, and with deductions for impairment. The effective interest rate is the interest rate that, when discounting all future expected cash flows over the expected maturity, results in the initially recognized value of the financial asset or financial liability. Financial receivables and liabilities with short maturities are reported at nominal value without discounting.

The effective interest rate is the rate that, when discounting cash flow forecasts over the expected duration, produces the initial carrying amount for the financial asset or liability. Financial receivables and liabilities with short maturities are reported at nominal value with no discounting.

Cash and cash equivalent
Cash and cash equivalents include cash and bank balances as well as other short-term liquid investments that can easily be converted into cash and are subject to insignificant risk of changes in value. In order to be classified as cash and cash equivalents, the term may not exceed three months from the date of the acquisition. Due to the fact that bank funds are payable on demand, the accrued acquisition value corresponds to the nominal amount.

Cash flow statements
The cash flow statement is prepared in accordance with the indirect method. The reported cash flow comprises only transactions that entail incoming or outgoing payments.

Contingent liabilities
Disclosures about a contingent liability are provided when there is a possible obligation depending on whether some uncertain future event occurs, or when there is an existing obligation for which payment is not probable or the amount cannot be measured reliably.

Equity
Transaction costs directly attributable to the issue of new shares or warrants are recognized in equity as a deduction from the issue proceeds.

Warrant programs
The company has warrants programs directed towards senior executives and other key persons, see note 29. Warrants are acquired for consideration corresponding to its fair value calculated in accordance with the Black & Scholes valuation model.

Parent Company's accounting policies
The parent company's financial statements were prepared in accordance with the Swedish Annual Accounts Act, the Swedish Financial Reporting Board's RFR 2, Accounting for Legal Entities, and applicable statements from the Swedish Financial Reporting Board. RFR 2 requires the parent company to apply IFRS and statements as adopted by the EU as far as possible in its annual report for the legal entity. The changes to RFR 2 Accounting in legal entities that took effect on January 1, 2021 have not had a material impact on the parent Company's financial statements.

The differences between the Group's and the Parent Company's accounting principles are set out below. The accounting principles for the Parent Company set out below have been applied consistently in all periods in the Parent Company's financial reports.

Classification and presentation
The profit and loss account and balance sheet of the Parent Company are presented in accordance with the Swedish Annual Accounts Act. The differences compared to IAS 1, Presentation of Financial Statements, refer mainly to financial income and expenses, equity and the presentation of provisions as a separate item in the balance sheet.

Shares in group companies
In the Parent Company, shareholdings in Group companies are accounted for in accordance with the cost method of accounting. The transaction costs are included in the carrying amount of shareholdings in group companies. The dividend received is recognized in the income statement.

Shareholders' contributions
Shareholder contributions are reported directly in shareholders' equity of the receiving party and are capitalized in shares and participations of the rendering party, to the extent that there is no need to recognize impairment.

Financial instruments
The Parent Company does not apply IFRS 9, except when calculating the net realizable value of accounts receivable, contract assets and other receivables where the same principles for impairment testing and loss risk reserve are applied as in the Group. In the Parent Company, financial fixed assets are valued at acquisition value less any impairment losses and financial current assets at the lower of cost and fair value less costs to sell.

Leasing
The Parent Company intends to make use of the exception regarding the implementation of IFRS 16, Leasing, implying that all leasing agreements are reported as operational.

Note 3 Significant estimates and assessments

Corporate management makes assessments and estimates in preparing the financial statements. These affect the reported values of assets, liabilities, revenues and expenses. Actual outcomes may deviate from these estimates and assessments.

Capitalized development costs
Capitalized development costs are impairment tested at least once per year. Impairment testing assesses whether the unit's recoverable amount is greater than it's carrying amount. Recoverable amount has been calculated based on value in use, which is the present value of the unit's expected future cash flows. The assessment is that, in what remains of capitalized development expenses, there is great potential for future revenues and cash flows based on the Group's product development. The carrying amount of capitalized expenses amounts to 14 729 Tkr (20 899), see also Note 13.

Deferred tax assets
Deferred tax assets are reported for tax loss carryforwards only to the extent that it is probable that the amounts can be utilized against future taxable surpluses. Management has made the assessment that no deferred tax assets should be reported, due to the uncertainty of when in the future future tax surpluses will be able to occur. For more information on tax loss carryforwards in the Group and the Parent Company, see Note 12.

Note 4 Financial risks and financial instruments

FRISQ is a young development company that operates in, and is trying to change, a traditionally slow-moving industry by creating digital tools to enable interactive communication between participants in the healthcare chain. The Company's commercialization strategies may prove to be ineffective or misdirected, which may result in FRISQ's revenues being insufficient to finance its operations or commitments as they fall due. In the event the Company does not become profitable, the Company may need to restructure all or parts of its operations, revise its business plan and/or make various financing arrangements.

The responsibility for the Group's financing and financial risk management lies with the Board of Directors and is carried out by the CEO through the CFO. Risks are evaluated annually in conjunction with budgeting and on an ongoing basis throughout the year. Through its operations, the Group is exposed to various financial risks including credit risk, liquidity risk, currency risk and interest rate risk. The overarching goal is to minimize negative effects on consolidated profit or loss and manage risks cost-effectively.

Credit risk
Credit risk is the risk that parties with whom the Group has a receivable are unable to fulfill their obligations, thereby causing a financial loss for the Group. Account receivable are limited as of the balance sheet date, and there is no need for a provision for doubtful accounts receivable. The Company's credit risk is deemed to be low.

Liquidity risk
Liquidity risk is the risk that the Group may have difficulties in fulfilling its obligations related to the Group's expenses and liabilities. There is no guarantee that the Company will be able to obtain the necessary liquidity if the development itself is positive. The general market situation for liquidity supply is also of great importance.

The Group's cash and cash equivalents amount to 13 072 Tkr on the balance sheet date. After the end of the year, the company has carried out a direct issue and a rights issue but these will not ensures that the company has sufficient cash for the coming 12-month period in accordance with the latest forecast.

Maturity analysis of contractual payments for financial liabilities

Group 12/31/2021	Within three months	3-12 months	2-5 years	After 5 years	Total
Lease liabilities	805	2 414	6 439	0	9 658
Accounts payable	4 236	0	0	0	4 236
Other liabilities	1 111	0	0	0	1 111
Total	**6 152**	**2 414**	**6 439**	**0**	**15 005**

Group 12/31/2020	Within three months	3-12 months	2-5 years	After 5 years	Total
Lease liabilities	869	2 506	0	0	3 375
Accounts payable	5 159	0	0	0	5 159
Other liabilities	992	0	0	0	992
Total	**7 020**	**2 506**	**0**	**0**	**9 526**

The amounts in these tables are not discounted values and they also contain interest payments, which means that these amounts are not possible to reconcile with the amounts reported in the balance sheets. Interest payments are determined on the basis of the conditions that apply on the balance sheet date.

All financial liabilities in the parent company mature within three months.

Currency risk
Currency risk is the risk that fair values and cash flows may fluctuate with changes in the value of foreign currencies.

Transaction risk
The Group is exposed to various types of currency risks. The main exposure stems from the need to cover costs related to the US, and UK.

Translation risk
The foreign subsidiaries receive most of their revenues in the accounting currency. There is therefore a currency risk in the translation of foreign subsidiaries' assets. The Group is currently mainly exposed to USD and GBP fluctuations against the Swedish krona.

The effect of any translation fluctuations is currently considered to be small as the business is under start-up phase and the cost base will not be scaled up before adequate future revenue flows can be expected.

Interest risk
Interest rate risk is the risk that changes in market interest rates may have an adverse impact on results and cash flow. At year-end the Group had no outstanding liabilities to banks or other credit institutions, aside from reported lease liability. Operations are financed with equity. A portion of interest-bearing assets carry interest. A 0.5 percent change in the interest rate impacts consolidated profit/loss and would have an impact on comprehensive income of +/- 92 Tkr (192). The Company's interest rate risk is therefore marginal.

Capital risk

The Company's Board of Directors oversees the Group's capital structure and financial management, decides on issues concerning acquisitions, investments and financing, and continuously monitors the Group's exposure to financial risks. The Group's capital management objective is to ensure the Group's capacity to continue its operations in order to generate reasonable returns for shareholders and benefits for other stakeholders. Neither the parent com-pany nor the subsidiary are subject to external capital requirements. The Group's current policy is not to distribute any dividend. A dividend distribution will not be proposed until the Company achieves long-term profitability.

Financial instruments by category

	Group		Parent company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Financial assets (valued at accrued acquisition value)				
Accounts receivables	1 259	1 994	0	0
Receivables from group companies	0	0	600	712
Other receivables	960	414	0	0
Accrued income (contractual revenues)	13	0	0	0
Cash and cash equivalents	13 072	87 811	10 397	68 924
Total	**15 304**	**90 219**	**10 997**	**69 636**
Financial liabilities (valued at accrued acquisition value)				
Lease liabilities	9 039	3 281	0	0
Accounts payable	4 236	5 159	455	1 112
Other liabilities	1 111	992	328	92
Accrued costs	3 391	2 525	48	90
Total	**17 777**	**11 957**	**831**	**1 294**

Valuation of financial instruments at fair value

The carrying amount of financial assets and financial liabilities is considered a good approximation of fair value, as the durations and/or fixed interest terms are short. Accordingly, discounting based on prevailing market conditions is not considered to have any significant effect.

Note 5 Disaggregation of revenue from contracts with customers

	Group		Parent company	
Net sales by category of revenue	**2021**	**2020**	**2021**	**2020**
Software licenses and implementation	4 891	1 367	0	0
Commissions	0	0	0	0
Intra-group sale	0	0	5 854	3 867
Total	**4 891**	**1 367**	**5 854**	**3 867**

Four customer each account for over 10% of net sales.

Note 6 Purchases and sales between group companies

Transactions between Group companies have been made on market terms and have been eliminated in the Group. The Parent Company has invoiced 5 854 Tkr (3 867) to other Group companies. The Parent Company has purchased from subsidiaries amounting to 28 Tkr (1 645) and pertained to reinvoiced expenses.

Note 7 Other operating income

	Group		Parent company	
	2021	**2020**	**2021**	**2020**
EU grants	1 549	407	0	0
Exchange rate difference	43	35	0	18
Other	4	0	0	0
Total	**1 596**	**442**	**0**	**0**

Note 8 Lease agreements

All lease agreements are reported in the balance sheet with the exception of short-term and low-value leases. At year-end closing the Group has lease agreements for premises that are reported as finance leases. Cars were included under reported leases part of 2020.

	Group	
Impact on earnings, IFRS 16	**2020**	**2019**
Amounts reported in profit and loss statement		
Amortization of rights of use	3 128	3 272
Interest expense, lease liability	60	221
Costs attributable to variable lease payments that are not included in the valuation of the lease liability	320	320
Costs attributable to low-value lease agreements	41	40
Costs attributable to short-term lease agreements	158	134
Total	**3 707**	**3 987**

The Group's commitments under short-term lease agreements amounted to 41 Tkr (49) per December 31, 2021. Total cash-flow for lease agreements excluding interest expenses totaled 3 341 Tkr (3 257).

Note 9 Auditor's fees

	Group		Parent company	
	2021	**2020**	**2021**	**2020**
Mazars AB				
Auditing fees	406	662	40	80
Total	**406**	**662**	**40**	**80**

Audit engagement refers to the work of auditors for the statutory audit and audit business refers to different types of quality assurance services. Other services are services not included in audit engagements, audit business or tax advisory services.

Frisq Holding AB (publ)
556959-2867

Note 10 Number of employees and employee benefits expense

Average number of employees	2021 Number of employees	2021 Thereof men	2020 Number of employees	2020 Thereof men
Parent company	0	0	0	0
	0	**0**	**0**	**0**
Subsidiaries				
Sweden	23	12	31	20
United States	0	0	0	0
Unitek Kingdom	0	0	0	0
	23	**12**	**31**	**20**
Total in the Group	**23**	**12**	**31**	**20**

	Group		Parent company	
	Dec 31, 2020	Dec 31, 2019	Dec 31, 2020	Dec 31, 2020
Distribution of Board members and senior executives at the balance-sheet date				
Board members	4	4	4	4
Thereof women	0	0	0	0
Group Management, including CEO	8	8	8	8
Thereof women	5	1	5	1

	Group		Parent company	
	2021	2020	2021	2020
Salaries and other remuneration				
The board and the CEO	11 328	12 917	1 530	2 609
Of which, bonus	0	7	0	0
Senior executives	12 414	18 547	0	0
Other employees	0	0	0	0
Total	**23 742**	**31 464**	**1 530**	**2 609**
Social security expenses				
Pension costs board of Directors, CEO, Management	625	362	204	0
Pension costs other employees	1 349	1 334	0	0
Other social security expenses	5 913	6 821	510	174
Total	**7 887**	**8 517**	**714**	**174**
Total salaries, remuneration and pensions	**31 629**	**39 981**	**2 244**	**2 783**

Where remuneration to management group members is invoiced, payroll overhead is included in the amount of pay reported, why total remuneration reported in Note 10 exceeds personnel costs as reported in the profit and loss statement. Such remuneration is reported as base salary. Agreements are based on generally accepted commercial terms.

Remuneration of the CEO, Group Management and senior executives - 2021	Base salary/ board fees	Variable remuneration	Pension-costs	Other remunerations	Total
Chairman of the Board					
Mats Lindstrand	200	0	0	0	200
Board members					
Per Egon Johansson	100	0	0	0	100
Lars Björk	100	0	0	0	100
Göran Hägglund	100	0	0	240	340
CEO					
George Thaw	4 287	0	0	0	4 287
Other senior executives (7)	6 541	0	625	7	7 173
Total	**11 328**	**0**	**625**	**247**	**12 200**

Remuneration of the CEO, Group Management and senior executives - 2020	Base salary/ board fees	Variable remuneration	Pension-costs	Other remunerations	Total
Chairman of the Board					
Mats Lindstrand	200	0	0	300	500
Board members					
Per Egon Johansson	100	0	0	0	100
Lars Björk	100	0	0	0	100
Göran Hägglund	100	0	0	240	340
Åke Hallman (avgått under året)	135	0	0	0	135
Anna Frick (avgått under året)	77	0	0	0	77
CEO					
George Thaw (August-December)	1 897	0	0	0	1 897
Martin Irding (January-July)	1 001	0	35	2	1 038
Other senior executives (6)	9 300	7	327	10	9 644
Total	**12 910**	**7**	**362**	**552**	**13 831**

Directors, CEO, Managment

Directors' fees are reported at basic pay/directors' fee in the table and consulting fees invoiced by board members are reported as other remuneration. Göran Hägglund provided operational consulting services in addition to his work as board member; this was invoiced from own companies.

The Director Lars Björk has received, in addition to the board fee, 320,000 warrants without paying any warrant premium. The warrants are earned over three years. Each warrant carries the right to subscribe to one new share, by 15 April 2026, at a price of 11.44 SEK. For more information see note 23.

Pension obligations

The company has no pension commitments neither to the current or former Board, CEO or other senior executives.

Severance pay agreement

The Company and CEO have a mutual notice period of three months with no contractual provisions for severance pay.

Note 11 Depreciation and write-down of tangible and intangible assets

	Group		Parent company	
	2021	2020	2021	2020
Capitalised expenditure for development and similar work	-16 595	-25 353	0	0
Goodwill	0	-104 490	0	0
Equipment	-239	-245	0	0
Right of use assets	-3 128	-3 272	0	0
Total	**-19 962**	**-133 360**	**0**	**0**

Group's total depreciation and amortization of tangible and intangible assets amounted to 19 962 Tkr (133 360) for the full year, of which 0 Tkr (104 490) relates to impairment of goodwill

Note 12 Income tax

	Group		Parent company	
	2021	2020	2021	2020
Deferred tax	0	-20 936	0	0
Reported tax	**0**	**-20 936**	**0**	**0**

Difference between tax at current tax rate and reported tax expense is shown in the table below.

	Group 2021	Group 2020	Parent company 2021	Parent company 2020
Profit/loss before tax	-80 386	-208 179	-58 565	-389 214
Tax based on applicable tax rate 20,6% (21,4%)	16 560	44 550	12 064	83 292
Tax effect of:				
Non-deductible expenses	-244	-2 237	-10 753	-81 327
Non-taxable income	378	0	0	0
Deductible expenses reported directly in equity	24	2 311	24	2 311
Change in deferred tax	0	-20 936	0	0
Increase in loss carryforwards for current year	-16 750	-22 263	-1 335	-4 276
Goodwill	0	-22 361	0	0
Other	32		0	0
Reported tax	**0**	**-20 936**	**0**	**0**

Tax loss carryforwards in the Group at year-end closing amounted to 392 778 Tkr (311 468). For the Parent Company, tax loss carried forward at year-end closing amounted 49 277 Tkr (42 793). No deficits are limited in time.

Note 13 Capitalised expenditure for development and similar work

	Group Dec 31, 2021	Group Dec 31, 2020	Parent Dec 31, 2021	Parent Dec 31, 2020
Opening acquisition value	77 672	69 085	0	0
Acquired value upon acquisition	10 425	8 587	0	0
Closing accumulated aquisition value	**88 097**	**77 672**	**0**	**0**
Opening deprecition value	-56 773	-31 420	0	0
Depreciation for the year	-16 595	-25 353	0	0
Closing accumulated depreciation	**-73 368**	**-56 773**	**0**	**0**
Closing amount	**14 729**	**20 899**	**0**	**0**

Expenses for product development have been balanced with a total of 10 425 Tkr (8 587) for the development of FRISQ Care. Expenses for product development have been expensed with a total of 12 223 Tkr (14 459) for the development of Frisq Care.
The Board of Directors conducts an impairment test prior to each reporting date to ensure that the value of other intangible assets are not overstated. The impairment test is based on a cash flow forecast for calculation of value in use. The calculated value in use is then compared with the carrying amount. The assessment of future cash flow is based on assumptions about expected future economic conditions, future growth, operating margins and investment requirements. The calculated value is based on the Company's 2022 budget and financial forecasts through 2026. Cash flows beyond the five-year period are calculated using an estimated conservative long-term growth rate of 0 percent.

Future cash flows have been calculated with a discount factor of 13.4 percent (16.8 percent) before tax. The discount rate shall, inter alia, reflect market assessments of the time value of capital and company-specific risks. The determination of the discount rate uses a weighted average cost of capital that takes assumptions about risk-free interest rates, market risk premiums, capital structure, borrowing rate and current tax rate, into account.

Note 14 Equipment

	Group Dec 31, 2021	Group Dec 31, 2020	Parent company Dec 31, 2021	Parent company Dec 31, 2020
Opening acquisition value	1 745	1 798	0	0
Purchase	177	601	0	0
Sales/disposals	0	-654	0	0
Closing accumulated aquisition value	**1 922**	**1 745**	**0**	**0**
Opening deprecition value	-1 105	-913	0	0
Sales/disposals	0	53	0	0
Depreciation for the year	-239	-245	0	0
Closing accumulated depreciation	**-1 344**	**-1 105**	**0**	**0**
Closing amount	**578**	**640**	**0**	**0**
Equipment broken down by country: Sweden	578	640	0	0
Closing amount	**578**	**640**	**0**	**0**

Note 15 Right of use assets

	Group	
	Dec 31, 2021	Dec 31, 2020
Opening acquisition value	9 382	9 868
Acquired value	9 039	653
Sales/disposals	0	-1 139
Closing accumulated aquisition value	**18 421**	**9 382**
Opening acquisition value	-6 254	-3 154
Sales/disposals	0	172
Depreciation for the year	-3 128	-3 272
Closing accumulated depreciation	**-9 382**	**-6 254**
Closing amount	**9 039**	**3 128**

Note 16 Participation in Group companies

	Parent company	
	Dec 31, 2021	Dec 31, 2020
Opening acquisition value	29 063	267 063
Shareholders contribution	52 200	142 000
Write-downs for the year	-52 200	-380 000
Closing amount	**29 063**	**29 063**

	Parent company	
Company	Dec 31, 2021	Dec 31, 2020
Frisq AB	29 053	29 053
Frisq USA Holding Inc	10	10
Frisq LLC	-	-
Frisq PLC	-	-
Closing amount	**29 063**	**29 063**

Company	Share of capital/share of votes	Number of shares	Reg. number	Domicile
Frisq AB	100%	1 839	556783-5664	Stockholm
Frisq USA Holding Inc	100%		30-1211598	Delaware, US
Frisq LLC	100%		38-8132515	Delaware, US
Frisq PLC	100%		12745808	London, UK

Note 17 Accounts receivables and contractual assets

	Group		Parent company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Account receivables, gross	1 259	1 994	0	0
Provision for doubtful accounts receivable	0	0	0	0
Accrued income (contractual assets)	13	0	0	0
Total	**1 272**	**1 994**	**0**	**0**

Maturity analysis of outstanding	Group		Parent company	
accounts receivable	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Not due	1 211	1 994	0	0
1-30 days	61	0	0	0
31-90 days	0	0	0	0
91-180 days	0	0	0	0
More than 181 days	0	0	0	0
Total	**1 272**	**1 994**	**0**	**0**

The Group has not posted any losses from bad debt during the year. As of balance sheet day, trade receivables of 0 Tkr, none deemed to require impairment. The maximum exposure to credit risks at the balance sheet date is the fair value of trade receivables and contractual assets, which is consistent with the carrying amount. There are no pledges for reported receivables. Intra-group receivables are settled every month, why there is no risk of intergroup losses.

Note 18 Prepaid expenses and accrued income

	Group		Parent company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Prepaid rents	834	989	0	0
Prepaid insurance	150	278	11	17
Accrued income (contractual assets)	13	0	0	0
Other items	56	50	14	45
Total	**1 053**	**1 317**	**25**	**62**

Note 19 Cash and cash equivalents

	Group		Parent company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Cash in bank	13 072	87 811	10 397	68 924
Total	**13 072**	**87 811**	**10 397**	**68 924**

Note 20 Share Capital

	Change in number of shares	Change in share capital, SEK	Total number of shares	Total share capital, SEK	Quota value, SEK
Formation - 2014	1 000 000	50 000	1 000 000	50 000	0,05
New share issue - 2015	500 000	25 000	1 500 000	75 000	0,05
New share issue - 2015	1 000 000	50 000	2 500 000	125 000	0,05
New share issue - 2015	2 205 128	110 256	4 705 128	235 256	0,05
Issue of non-cash consideration - 2015	7 794 872	389 744	12 500 000	625 000	0,05
New share issue - 2016	1 922 500	96 125	14 422 500	721 125	0,05
New share issue - 2017	2 403 846	120 192	16 826 346	841 317	0,05
New share issue - 2017	100 000	5 000	16 926 346	846 317	0,05
New share issue - 2018	2 795 941	139 797	19 722 287	986 114	0,05
New share issue - 2018	495 915	24 796	20 218 202	1 010 910	0,05
New share issue - 2019	3 700 000	185 000	23 918 202	1 195 910	0,05
New rights issue -2020	8 286 571	414 329	32 204 773	1 610 239	0,05
New share issue - 2021	15 750 000	787 500	47 954 773	2 397 739	0,05

Each share in the Company entitles the holder to one vote at the general meeting of shareholders. Each shareholder is entitled to vote for all shares held by the shareholder in the Company, with no restrictions to voting rights. All shares in the Company confer equal rights to dividend and to the Company's assets and any surplus in the event of liquidation.

The new share issue, which was completed in November 2020, was registered in January 2021, with the number of shares increasing by 15 750 000 to 47 954 773.

Note 21 Other contributed capital

Other contributed capital has arisen when issues have been carried out at a premium. Issues carried out during 2021 increased contributed capital by 365 Tkr. In addition, issue costs have reduced contributed capital by 119 Tkr, which is attributable to the issue that was approved in November 2020.

Note 22 Proposed disposition of the Company's profit

	Parent company Dec 31, 2021
At the disposal of the general meeting, SEK	
share premium reserve	491 641 348
retained earnings	-396 369 355
net profit/loss for the year	-58 565 285
	36 706 708
The board of directors proposes the following to be carried forward	36 706 708
	36 706 708

Note 23 Earnings per share

	Group	
	Dec 31, 2021	Dec 31, 2020
Earnings per share before/after dilution (SEK)	-1,7	-7,3
Profit/loss attributable to ordinary equity holders of the company	-80 386	-229 115
Weighted average nr of shares outstanding before/after dilution	47 523 266	31 412 341

The options programs at FRISQ Holding aim to ensure consistent incentives for shareholders and employees. The options have been transferred at market prices at an independently determined valuation and are subject to customary conversion conditions in connection with issues. For further information see communiqués from previous annual general meetings.

Warrants 2017
Program 2017, a direct issue where warrants were issued to secure FRISQ's commitment, given fulfillment of certain conditions, to pay an additional consideration for the acquisition of new care path concepts, and associated code. It allows a maximum 1 100 000 warrants each entitling to the subscription of one share, by no later than 31 May 2022, at a price of 0.05 SEK corresponding to the share's quota value.

Warrants 2020/2026
Program 2020/2026, implemented for the Director Lars Björk and aims to offer ownership in the Company for his significant involvement in the establishment of FRISQ in the US. The program includes 320,000 warrants, of which 300,000 warrants are awarded to Lars Björk without consideration, and 20,000 are allocated to cover costs related to the program. The warrants are earned over three years. Each warrant carries the right to subscribe to a new share, by no later than 15 April 2026, at a price of 11.44 SEK.

Warrants 2021/2024
Program 2021/2024, with a maximum of 2,000,000 warrants, aimed at key employees and individuals in the Group. The subscription period is 1 January - 31 March 2024. Each warrant entitles the holder to subscribe to one share at a price corresponding to 200 % of the average volume weighted price 1-12 March 2021; but no lower than 9 SEK/share. If fully subscribed, the Company's share capital will increase by SEK 100 000.

Full subscription of the above programs would increase the total number of shares by 7,1%.

Other than the above-mentioned warrant programs, as of the balance sheet date there were no other outstanding warrants, convertibles or similar financial instruments that may entitle the holder to subscribe to new shares or otherwise affect the Company's share capital. Warrants have a dilutive effect, as they lead to the issue of ordinary shares at a below-average share price. With a conversion of potential ordinary shares for the current financial year, earnings per share will reduce this loss and, accordingly, there will be no dilution.

Note 24 Cash flow attributable to financing activities

	Group	
	Dec 31, 2021	Dec 31, 2020
Leasing debt		
Opening value	3 281	6 800
Cash-flow from financing activities		
Lease payments	-3 281	-3 257
Non-cash changes		
Acquisition of new lease contracts	9 039	653
Retired lease liability, non cash-flow item	0	-915
Closing value	**9 039**	**3 281**

Note 25 Leasing liabilities

	Group	
	Dec 31, 2021	Dec 31, 2020
Due within 1 year	2 867	3 281
Due within 2-5 years	6 172	0
Total	**9 039**	**3 281**

Note 26 Accrued expenses and deferred income

	Group		Parent company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Personnel-related costs	1 547	2 655	100	43
Accrued development expenditures/consultants' fees	2 224	614	0	0
Deferred income (contract with customers)	933	1 701	0	0
Other items	234	210	48	90
Total	**4 938**	**5 180**	**148**	**133**

Note 27 Collateral and contingent liabilities

	Group		Parent company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Pledged assets	None	None	None	None
Contingent liabilities	None	None	None	None

Note 28 Related-party transactions

Purchases and sales between the parent company and subsidiary have been eliminated in the Group; information on these transactions is presented in Note 6. The parent company has current receivables from subsidiaries amounting to 600 Tkr (712) and liabilities of 0 Tkr (0). Subsidiary FRISQ AB received an unconditional shareholders' contribution of 52 200 Tkr (142 000) from the Parent Company. Other than consulting services provided by management team members, there were no purchases or sales between the Group and related parties. Additional details, and information on remuneration to management team members and other related parties, is presented in Note 10.

Note 29 Events after the balance sheet date

• After a 12-month pilot project, Capio Orthopedics now signs a three-year agreement with FRISQ. The purpose of the agreement is to introduce the digital process support FRISQ Care in all Capio Orthopedics units in accordance with the with the offered licensing and implementation costs,

• The Extra General Meeting made an amendment of the Articles of Association, which gave the Board a mandate to issue new shares..

• The Company has carried out a directed share issue of 15.080,000 shares at the issue price of one (1) SEK per share. These shares are not entitled to any rights in the rights issue. The total number of shares issued in the directed issue and the forthcoming rights issue will total a maximum of approximately 31.9 million shares, which is covered by the authorization provided to the Board mandated by the recently held Extraordinary General Meeting. Given a subscription of a total of 31.9 million shares in the two new issues, the number of shares in the company will increase from 47,954,773 to 79,854,773. The shares issued in the directed issue and the rights issue will constitute approximately 40 percent of the shares in the Company.

Total cost for both the rights issue and the direct issue will approximately be 0.8 mSEK. The Company will, at full subsription of the new shares, receive a net financing of 31 .

With these new share issues, the Company is trying to secure the financial position. The Board has begun to work together with the management team to adjust costs and focus the commercial work with objective that the Company will be cash flow positive by the end of 2022.Tempest has indicated that they still are interested in purchasing Frisq subsidiaries. The Board cannot assess the probablilty that this will happen.

Note 30, Definition of ratios

Operating income
Earnings before net financial items.

Earnings per share after dilution
Income attributable to the Parent Company's shareholders divided by the weighted average number of outstanding shares during the period after dilution.

Earning per share before dilution
Income attributable to the Parent Company's shareholders divided by the weighted average number of outstanding shares in the period prior to dilution.

Equity/asset ratio %
Equity as a percentage of the balance sheet total

Frisq Holding AB (publ)
556959-2867

The Board and the CEO hereby certify that the annual report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2 Financial reporting for legal entities, and gives a true and fair view of the company's position and performance, and that the management report gives a fair overview of the development of the company's performance, position and results, and describes the material risks and uncertainties that the company faces. The Board and the CEO hereby certify that the consolidated financial statement has been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU, and gives a true and fair view of the group's position and performance, and that the group's annual report gives a fair overview of the development of the group's performance, position and results, and describes the material risks and uncertainties faced by the companies that are part of the group.

Stockholm April 14, 2022

Mats Lindstrand
Chairman

Per Egon Johansson
Board Member

Lars Björk Board
Member

Göran Hägglund
Board Member

George Thaw
CEO

Our audit report was submitted on April 14, 2022

Mazars AB

Samuel Bjälkemo
Authorized Public Accountant